Creative Biolabs provides antifungal persister cell and drug tolerance assay services for hit-to-lead, resistance-mechanism, and combination-screening programs. We help teams move beyond MIC-only decisions by quantifying survival kinetics, tolerant subpopulations, and rescue potential under assay conditions matched to the fungal species, drug class, exposure window, specific development question, and next decision.
Antifungal discovery teams often see acceptable MIC results long before they know whether a compound can suppress the small surviving populations that drive rebound, biofilm persistence, and apparent treatment failure in translational models. Hit-to-lead programs therefore need assays that separate routine growth inhibition from delayed killing, tolerant outgrowth, and persister survival.
For resistance-research groups and antifungal developers, the priority is a decision-ready data package: time-dependent killing curves, persister quantification, tolerance indexing, and combination-rescue evidence that can guide chemistry, mechanism studies, and follow-on efficacy work. Creative Biolabs provides a tailored antifungal persister cell and drug tolerance assay service to build that evidence efficiently.
We design assay modules around the scientific question, not a fixed susceptibility template. Each study can be configured for planktonic cells, mature biofilms, post-exposure survivors, or model-specific fungal states, with readouts selected to reveal whether a candidate simply delays growth or genuinely reduces drug-tolerant survival.
Creative Biolabs establishes species- and strain-appropriate time-kill assays for Candida, Aspergillus, and other fungal pathogens as required by the program. We test drug exposure across selected multiples of MIC, collect time-point CFU or viability readouts, and distinguish rapid fungicidal activity from slow attrition, delayed regrowth, or plateau behavior. This module is especially useful when a compound looks active in endpoint susceptibility testing but its killing trajectory remains unclear.
Candidate compound, reference antifungal, isolate panel, target exposure range, and current MIC or pilot susceptibility data.
Log survival curves, kill-rate comparison, rebound flags, and interpretation notes for lead triage.
Persister-enriched assays quantify the surviving fraction after high-dose or prolonged antifungal challenge. Depending on the model, we can evaluate biofilm-associated persisters, amphotericin B-tolerant survivors, azole-tolerant subpopulations, and post-treatment regrowth behavior using CFU recovery, viability staining, metabolic readouts, or microscopy-supported confirmation.
We convert slow-growth or survivor signals into decision-friendly tolerance metrics, including persistence fraction, area-under-kill-curve comparisons, tolerance index summaries, and isolate-to-isolate ranking when panels are tested.
For combination strategies, we compare single-agent and paired-drug exposure to identify rescue of killing activity, reduced tolerant outgrowth, and mechanistic clues for synergy follow-up. Designs can be aligned with antifungal MoA hypotheses.
When relevant, assays are adapted to biofilm maturity, nutrient stress, oxygen conditions, matrix-associated protection, or post-exposure recovery windows so that tolerance readouts better reflect the program's biological question.
Determine whether MIC activity translates into measurable killing against the target fungal state.
Compare candidate series by survivor burden, kill slope, and tolerance behavior.
Connect survivor patterns to membrane, stress-response, efflux, biofilm, or metabolism hypotheses.
Prioritize partner drugs that reduce tolerant outgrowth and improve killing depth.
Our deliverables are built for practical go/no-go decisions. Instead of returning isolated plate counts, we organize the data into a clear package that explains assay conditions, survivor behavior, tolerance signals, and next-step recommendations for discovery and preclinical research teams.
| Data Component | What It Clarifies | Program Value |
|---|---|---|
| Time-kill curve report | Killing depth, kill slope, plateau formation, and post-exposure rebound across time points. | Shows whether MIC activity is strong enough to justify further optimization. |
| Persister fraction summary | Surviving cell burden after high-dose or prolonged drug exposure in selected fungal states. | Identifies candidates that leave a problematic tolerant reservoir. |
| Drug tolerance index | Quantitative comparison of tolerant outgrowth or delayed inhibition across isolates, compounds, or conditions. | Supports compound ranking and isolate-panel interpretation. |
| Combination rescue profile | Whether a second agent restores killing, reduces survivor fraction, or improves recovery suppression. | Guides synergy screens and mechanistic follow-up experiments. |
A controlled workflow keeps the assay interpretable from intake through report delivery, especially when multiple isolates, drug classes, or combination conditions are being compared.
Confirm fungal species, isolate status, compound format, comparator drug, exposure window, and tolerance question.
Prepare planktonic, biofilm, stress-state, or recovery models with pilot checks for inoculum, controls, and readout dynamic range.
Run timed drug exposure, washout or neutralization where needed, viable recovery, staining, microscopy, or metabolic measurement.
Deliver plots, survivor metrics, tolerance interpretation, and suggested next assays for MoA or combination validation.
Recent research on Candida albicans biofilm persisters shows why antifungal programs need readouts beyond endpoint susceptibility. The published data connect high-dose amphotericin B survivor assays with viable cell recovery, SOD2 expression, ROS measurement, manganese superoxide dismutase activity, and fluorescence imaging, showing that persister survival can remain measurable even under aggressive drug exposure.
The figure shows assay endpoints that separate persister survival from simple growth inhibition and links survivor burden to stress-response biology. Creative Biolabs can provide related antifungal persister cell and drug tolerance assay support, including time-kill profiling, persister quantification, drug tolerance indexing, and combination-rescue testing for early antifungal development programs.
Our antifungal testing support is structured for teams that need reliable, decision-ready data rather than a generic assay snapshot.
Study conditions are adapted to the compound class, fungal state, isolate panel, and specific tolerance question.
CFU, viability, metabolic, microscopy, and recovery data can be combined to avoid overinterpreting a single signal.
Tolerance assays can be linked to synergy and MoA work so that rescue signals lead naturally into follow-up studies.
Reports emphasize plots, metrics, assay limitations, and actionable next steps for hit-to-lead and resistance programs.
Persister and tolerance data become more useful when they are interpreted alongside susceptibility, mechanism, and combination evidence. These related services can be paired with the current assay plan when your program needs a broader antifungal data package.
These assays are most useful after initial susceptibility confirmation, when the team needs to know whether surviving fungal cells remain after drug exposure, whether killing plateaus, or whether a combination can reduce tolerant outgrowth.
MIC testing measures visible growth inhibition at an endpoint. Persister and tolerance assays follow survival over time, recovery after exposure, and residual viable populations that may not be obvious from MIC data alone.
Yes. We can compare single-agent and paired-drug exposure to evaluate whether the combination improves killing depth, reduces survivor fraction, or suppresses recovery under defined assay conditions.
Depending on the project, assays can be configured for planktonic cultures, biofilm models, post-treatment survivors, isolate panels, or stress-state conditions that support the intended research question.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2026 Creative Biolabs. All Rights Reserved.